Payment overview · 2025
General Payments
$180.17
11 reported records · 7 companies
Healthcare provider profile · identity verified
Manish B Joshi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AUSTINTOWN, OH · NPI 1952384679
Verified facts
What the public records show
CMS Open Payments records show Manish B Joshi, MD received $180.17 in general payments during 2025 across 11 reported records.
PFIZER INC. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.70 | 25.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.95 | 19.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.81 | 16.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.68 | 12.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.70 | 9.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.53 | 9.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.80 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $180.17 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.70 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.95 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $29.04 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.81 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.81 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.68 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 164 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 438 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 386 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 82 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 296 | 49 |
| Metformin Hcl | Metformin Hcl | 276 | 62 |
| Losartan Potassium | Losartan Potassium | 259 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 57 |
| Alprazolam | Alprazolam | 184 | 35 |
| Tramadol Hcl | Tramadol Hcl | 184 | 35 |
| Simvastatin | Simvastatin | 183 | 44 |
| Furosemide | Furosemide | 181 | 43 |
| Gabapentin | Gabapentin | 180 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 166 | 34 |
| Eliquis | Apixaban | 164 | 29 |
| Lisinopril | Lisinopril | 156 | 37 |
| Omeprazole | Omeprazole | 156 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 39 |
| Potassium Chloride | Potassium Chloride | 140 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 135 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 119 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 18 |
| Montelukast Sodium | Montelukast Sodium | 77 | 17 |
| Famotidine | Famotidine | 72 | 16 |
| Methylprednisolone | Methylprednisolone | 72 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 16 |
| Ozempic | Semaglutide | 70 | 13 |
| Trazodone Hcl | Trazodone Hcl | 69 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | 19 |
| Jardiance | Empagliflozin | 67 | 13 |
| Donepezil Hcl | Donepezil Hcl | 65 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 12 |
| Diazepam | Diazepam | 63 | 11 |
| Meloxicam | Meloxicam | 63 | 12 |
| Mirtazapine | Mirtazapine | 63 | 15 |
| Azithromycin | Azithromycin | 60 | 47 |
| Lorazepam | Lorazepam | 59 | 12 |
| Atenolol | Atenolol | 58 | 15 |
| Glimepiride | Glimepiride | 54 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 13 |
| Allopurinol | Allopurinol | 51 | 12 |
| Synthroid | Levothyroxine Sodium | 50 | 11 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Carvedilol | Carvedilol | 47 | 12 |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 34 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Lidocaine | Lidocaine | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 13 |
| Amoxicillin | Amoxicillin | 17 | 11 |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cetirizine Hcl | Cetirizine Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Sulindac | Sulindac | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | 11 |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Easy Touch | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $180.17 · 11 records | PFIZER INC. | ELIQUIS, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, XIFAXAN, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error